

## FULL PAPER

**Anti-Inflammatory Activity of a Novel Acetylene Isolated from the Roots of *Angelica tenuissima* NAKAI**by Hyun Gyu Choi<sup>a)</sup>, Hyukjae Choi<sup>b)</sup>, Jeong-Hyung Lee<sup>c)</sup>, Byung Sun Min<sup>d)</sup>, and Jeong Ah Kim<sup>\*a)</sup><sup>a)</sup> College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 702-701, Korea (phone: +82-53-950-8574; fax: +82-53-950-8557; e-mail: jkim6923@knu.ac.kr)<sup>b)</sup> College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk 712-749, Korea<sup>c)</sup> College of Natural Sciences, Kangwon National University, Gangwon-Do 200-701, Korea<sup>d)</sup> College of Pharmacy, Catholic University of Daegu, Gyeongsan 712-702, Korea

Three polyacetylenes, one novel and two known, were isolated from the root of *Angelica tenuissima*. Using <sup>1</sup>H- and <sup>13</sup>C-NMR, COSY, HMBC, and HMQC, their structures were found to be (3*R*,8*S*)-heptadeca-1-en-4,6-diyne-3,8-diol (**1**), faltarindiol (**2**), and oplopandiol (**3**). Absolute configurations of compound **1** were established using Mosher's esterification. In addition, the polyacetylenes (**1** – **3**) were evaluated for their anti-inflammatory activity. Compounds **1** and **3** showed potent inhibitory activity against lipopolysaccharide-induced nitric oxide (NO) production in RAW267.7 macrophage cells with *IC*<sub>50</sub> values of 4.31 and 5.06 μM, respectively. Compound **1** strongly inhibited inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 in a concentration-dependent manner.

**Keywords:** *Angelica tenuissima*, Polyacetylenes, NO, iNOS, COX-2.

**Introduction**

*Angelica tenuissima* NAKAI (*Ligusticum tenuissimum* KITAGAWA), belongs to the Apiaceae family and is native to Asia. It is used in traditional medicine to treat headache, diarrhea, epilepsy, and rheumatic arthralgia [1]. Many examples of its effects are found in the literature. For example, in a model of Parkinson's disease, a Korean herbal formula containing *A. tenuissima* extract has been shown to have neuroprotective effects that are partially mediated by the enhancement of autophagy [2]. In addition, a volatile extract of this plant has been shown to have antioxidant activity [3]. Chemical studies have indicated that *A. tenuissima* contains phthalides, coumarins, terpenoids, and phenylpropanoids [3][4]. The phthalide, (*Z*)-ligustilide showed anti-inflammatory activity in experiment with lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages [5]. This was the first study to report the isolation of polyacetylenes from *A. tenuissima*. Conjugated acetylenes from other plants have been shown to possess a variety of biological activities, including antitumor, anti-inflammatory, and antimicrobial effects [6]. For example, acetylenes isolated from the root of *Echinacea pallida* have anticancer activity when applied to MIA PaCa-2 and COLO320 cells [7]. Furthermore, oploxynes A and B extracted from *Oplopanax elatus* inhibited the formation of nitric oxide (NO) and prostaglandin E<sub>2</sub> in LPS-treated RAW 267.7 murine macrophage cells [8].

While the roots of *A. tenuissima* have shown to contain many types of compounds, the polyacetylene content of this plant has not been reported. In this study, we have isolated the novel polyacetylene, (3*R*,8*S*)-heptadeca-1-en-4,6-diyne-3,8-diol (**1**) from *A. tenuissima*. Since this compound is structurally similar to the known anti-inflammatory compounds oploxynes A and B, we hypothesized that it may have similar activity. To evaluate the anti-inflammatory effect of the polyacetylenes, we studied their inhibition of NO, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in LPS-treated RAW 267.7 murine macrophage cells.

**Results and Discussion***Elucidation of Chemical Structures*

Polyacetylenes (**1** – **3**, Fig. 1) were purified using silica gel column chromatography (CC) and preparative HPLC. To determine the chemical structure of **1**, HR-CI-MS and 500-MHz NMR, including <sup>1</sup>H, <sup>13</sup>C, COSY, HMQC, and HMBC, were performed. The <sup>1</sup>H- and <sup>13</sup>C-NMR data are described in the Table. Absolute configurations of compound **1** were elucidated by Mosher's esterification.

Compound **1** was obtained as a colorless oil. The molecular formula of **1** was found to be C<sub>17</sub>H<sub>26</sub>O<sub>2</sub> according to HR-CI-MS (obsd. [*M* – H]<sup>+</sup> at *m/z* 261.1855). The <sup>1</sup>H-NMR spectrum of compound **1** indicated the presence




Fig. 1. Chemical structures of compounds 1 – 3.

Table.  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectral data of compound 1

| Position         | $\delta(\text{H})$ ( $J$ in Hz) <sup>a)</sup>  | $\delta(\text{C})$ <sup>b)</sup> |
|------------------|--|----------------------------------|
| 1                | 5.27 ( <i>dt</i> , $J = 10.2, 1.0$ ),<br>5.48 ( <i>ddd</i> , $J = 17.0, 1.4, 1.0$ )<br>5.95 ( <i>ddd</i> , $J = 17.0, 10.2, 5.4$ ) | 117.5                            |
| 2                | 4.94 ( <i>d</i> , $J = 5.3$ )  | 135.9                            |
| 3                | –  | 63.6                             |
| 4                | –  | 77.9                             |
| 5                | –  | 70.4                             |
| 6                | –  | 68.8                             |
| 7                | –  | 81.3                             |
| 8                | 4.43 ( <i>t</i> , $J = 6.6$ )  | 63.0                             |
| 9                | 1.72 ( <i>dt</i> , $J = 14.0, 6.7$ )   | 37.6                             |
| 10 <sup>c)</sup> | 1.40 – 1.46 ( <i>m</i> )   | 25.1                             |
| 11 <sup>c)</sup> | 1.40 – 1.46 ( <i>m</i> )   | 29.3                             |
| 12 <sup>c)</sup> | 1.26 – 1.31 ( <i>m</i> )   | 29.4                             |
| 13 <sup>c)</sup> | 1.25 ( <i>s</i> )  | 29.6                             |
| 14 <sup>c)</sup> | 1.25 ( <i>s</i> )  | 29.6                             |
| 15 <sup>c)</sup> | 1.25 ( <i>s</i> )  | 32.0                             |
| 16 <sup>c)</sup> | 1.25 ( <i>s</i> )  | 22.8                             |
| 17               | 0.88 ( <i>t</i> , $J = 7.0$ )  | 14.3                             |

<sup>a)</sup> Recorded at 500 MHz ( $\text{CDCl}_3$ ). <sup>b)</sup> Recorded at 125 MHz ( $\text{CDCl}_3$ ).

<sup>c)</sup> Overlapped signals. All assignments were confirmed by HMQC and HMBC experiments.

of three olefinic H-atoms (5.95, 5.48, and 5.27 ppm), two oxymethylene H-atoms (4.94 and 4.43 ppm), eight aliphatic H-atoms (1.72, 1.40 – 1.46, 1.26 – 1.28, and 1.25 ppm), and one Me (0.88 ppm). The  $^{13}\text{C}$ -NMR spectrum showed the presence of two olefinic C-signals (135.9 and 117.5 ppm), a conjugated diyne (81.3, 77.9, 70.4, and 68.8 ppm), two oxymethylene signals (63.6, and 63.0 ppm), eight aliphatic  $\text{CH}_2$ -signals (37.6, 32.0, 29.6, 29.6, 29.4, 29.3, 25.1, and 22.8 ppm), and a Me-signal (14.3 ppm). Further analysis suggested that the two olefinic H-atom signals at 5.48 ppm (*ddd*,  $J = 17.0, 1.4, 1.0$  Hz, 1 H) and 5.27 (*dt*,  $J = 10.2, 1.0$  Hz, 1 H) correlated with the  $^{13}\text{C}$ -NMR signal at 117.5 ppm (C(1)) in the HMQC spectrum. The  $^1\text{H},^1\text{H}$ -COSY spectrum showed that these two olefinic H-atoms correlated with protons at 5.95 (*ddd*,  $J = 17.0, 10.2, 5.4$  Hz, 1 H). The oxymethylene signal at 4.94 ppm (*d*,  $J = 5.3$  Hz, 1 H) correlated with the signal at 5.95 ppm. In the HMBC spectrum, the oxymethylene signal at 4.94 ppm correlated with the two olefinic C-signals at 135.9 and 117.5 ppm, and the conjugated diyne signals (81.3, 77.9, 70.4, and 68.8 ppm as shown in Table). In addition, the oxymethylene signal at 4.43 (*t*,  $J = 6.6$  Hz, 1 H) correlated with the four alkynyl C-signals at 81.3, 77.9, 70.4, and 68.8 ppm and the aliphatic signals at


37.6 and 25.1 ppm (Fig. 2). Thus, the compound was identified as heptadeca-1-en-4,6-diyne-3,8-diol.

The absolute configurations of C(3) and C(8) of compound 1 were assigned on the basis of chiral derivatization followed by NMR analysis. Treatment of 1 with (*R*)-MTPACI and DMAP in pyridine yielded an (*S*)-MTPA ester (1a). Similar treatment of 1 with (*S*)-MTPACI afforded an (*R*)-MTPA ester (1b). Analysis of the  $^1\text{H}$ -NMR chemical shift differences between  $\delta(\text{S})$  and  $\delta(\text{R})$  allowed the assignment of the absolute configurations of C(3) and C(8) of 1 as (*R*) and (*S*), respectively (Fig. 3). Therefore, the structure of compound 1 was elucidated as (3*R*,8*S*)-heptadeca-1-en-4,6-diyne-3,8-diol.

Compounds 1 – 3 had similar NMR spectra, but the numbers of C=C bonds in compounds 2 and 3 were different from that of 1. The  $^1\text{H}$ -NMR spectrum of compound 2 showed five H-atom signals at 5.92, 5.60, 5.50, 5.46, and 5.24 ppm. The olefinic H-atom signal at 5.60 ppm (*dt*,  $J = 10.6, 7.5$  Hz, 1 H, H-C(9)) in compound 2 indicates a *Z*-configuration; the rest of the  $^1\text{H}$ -NMR spectra was similar to that of compound 1. Therefore, the chemical structure of 2 was determined to be falcariindiol (2) based on comparison with previously reported data [8]. The structure of compound 3 was determined based on comparison to that of 1 and 2. The key difference between the spectra of compounds 1 and 3 was the presence of two olefinic H-atoms in compounds 3 (5.55 ppm, *ddd*,  $J = 11.0, 8.0, 1.0$  Hz, 1 H, H-C(10); 5.47 ppm, *ddd*,  $J = 11.0, 8.5, 1.0$  Hz, 1 H, H-C(9)), in place of the terminal olefinic  $\text{CH}_2$  group seen in compound 1. The coupling constant (11.8 Hz) between H-C(9) and H-C(10) suggested a *cis*-configuration for the C=C bond. Therefore, compound 3 was determined to be oplopandiol (3) in agreement with previously reported data [8].

#### Anti-Inflammatory Activity of Compounds 1 – 3

Activated inflammatory cells (neutrophils, eosinophils, mononuclear phagocyte, and macrophages) express many

Fig. 2.  $^1\text{H},^1\text{H}$  COSY (—) and key HMBC (---) correlations of compound 1.




Fig. 3.  $\Delta\delta(S - R)$  Values for the bis-Mosher esters **1a/1b**, in  $(D_5)$ pyridine.

biomolecules including NO, prostaglandin  $E_2$  ( $PGE_2$ ), and cytokines, such as interleukin (IL)-6,  $1\beta$ , and tumor necrosis factor (TNF)- $\alpha$ . These signaling molecules play a role in activating macrophages and may lead to tissue damage.  $PGE_2$  is a major inflammatory mediator and is produced by the catalysis of COX-2. NO is another important inflammatory substance. Its synthesis is controlled by several types of NOS. Accordingly, reducing iNOS and COX-2 expression, and thus inhibiting the production of NO and other inflammatory mediators, is the principle mechanism of action of anti-inflammatory agents.

The roots of *A. tenuissima* were previously reported to have an inhibitory effect on the expression of COX-2 and NO synthase in BV2 murine microglial cells [9]. Additionally, the isolated compounds, falcariindiol (**2**) and oplopandiol (**3**), were reported to have anti-inflammatory activity in LPS-treated RAW 267.7 murine macrophage cells [8]. Therefore, we evaluated their effect on the production of NO, iNOS, and COX-2.

As shown in Fig. 4, compounds **1** and **3** strongly inhibited the production of NO in a concentration-dependent manner with  $IC_{50}$  values of 4.31 and 5.06  $\mu M$ , respectively. This effect resulted from the inhibition of LPS-induced iNOS production in macrophage cells. Compound **2** did not have any inhibitory effect. Western blotting was performed to determine the effects of compound **1** and **3** on COX-2 expression. Compounds **1** and **3** suppressed LPS-induced COX-2 expression in a concentration-dependent manner.

In summary, in this study, we have isolated for the first time a family of polyacetylenes from *A. tenuissima*. Their chemical structures were elucidated using spectroscopic methods and chemical techniques. Polyacetylenes **1** and **3** effectively suppressed proinflammatory mediators including NO, iNOS, and COX-2 and have potential as therapeutic anti-inflammatories. The results of this work also support the observation that *A. tenuissima* has anti-inflammatory activities.

This research was supported by the *Traditional Korean Medicine R&D Program* funded by the *Ministry of Health & Welfare* through the *Korea Health Industry Development Institute* (KHIDI; HI15C0255) and the *National Research Foundation of Korea (NRF)*, funded by the

*Ministry of Science, ICT, and Future Planning* (NRF-2015M3A9A5031271).

## Supporting Information

Additional Supporting Information (Supplementary spectral data of compound **1** (1D and 2D NMR, HR-CI-MS)) may be found in the online version of this article: DOI: 10.1002/hlca.201500507

## Experimental Part

### General

TLC: silica gel 60F<sub>254</sub> and RP-18 F<sub>254s</sub> silica gel plates (Merck, Darmstadt, Germany); detection under UV light and by spraying with vanillin-sulfuric acid reagent (1% ethanolic vanillin soln/10% ethanolic sulfuric acid) and 10% H<sub>2</sub>SO<sub>4</sub> reagent, followed by heating at 110 °C for 1 min. Column chromatography (CC): silica gel (SiO<sub>2</sub>; 70 – 230 mesh; Merck, Germany) and Lichroprep RP-18 gel (40 – 63  $\mu m$ ; Merck, Darmstadt, Germany). HPLC: prep. HPLC Gilson system (Gilson, Middleton, WI, USA) 321 pump, UV/VIS-155 detector, FC 204 fraction collector, Phenomenex-Luna-C18 column (250  $\times$  21.20 mm, 10  $\mu m$ );  $t_R$  in min. Optical rotation: JASCO DIP-1000 polarimeter (JASCO, Tokyo, Japan). <sup>1</sup>H- and <sup>13</sup>C-NMR spectra: Bruker DMX 250 (Rheinstetten, Germany) or Jeol ECA-500 NMR spectrometer (Jeol, Tokyo, Japan); (in ppm rel. to tetramethylsilane (TMS) as internal standard,  $J$  in Hz at 298 K. HR-CI-MS: Jeol JMS-600W, chemical ionization (CI), gas chromatography/mass spectrometer (Jeol, Japan).

### Plant Material

*Angelica tenuissima* roots were purchased from Yak-Ryung-Si Market in Daegu, Korea and identified by Dr. Seung Ho Lee at the College of Pharmacy, Yeungnam University. A voucher specimen (YU00192) has been deposited with the Natural Product Laboratory at the College of Pharmacy, Yeungnam University, Korea.

### Extraction and Isolation

Dried roots of *A. tenuissima* (8.7 kg) were extracted with MeOH (25 l  $\times$  3) at r.t. The extract was concentrated *in vacuo* to afford a black gum (1.8 kg), which was dissolved in H<sub>2</sub>O, continuously partitioned with solvents, then concentrated to give extracts of CH<sub>2</sub>Cl<sub>2</sub> (334.1 g), AcOEt (24.5 g), and H<sub>2</sub>O (1.4 g). The CH<sub>2</sub>Cl<sub>2</sub>-soluble extract (334.1 g) was separated using SiO<sub>2</sub> vacuum liquid chromatography eluted with a gradient mixture of 100% hexanes to 100% AcOEt to afford eight fractions (AT1 – AT8). Fr. AT4 (40.0 g) was separated on an open




Fig. 4. Anti-inflammatory activities of compounds **1** – **3**. Inhibition of NO production a) and LPS-Induced iNOS and COX-2 expression b) in macrophage RAW264.7 cells by compounds **1** – **3**. RAW264.7 cells were pretreated for 30 min indicated concentrations of **1** – **3**, followed by stimulation with LPS (1 µg/ml) for 18 h. Total lysates were prepared, the expression levels of iNOS and COX-2 were determined by western blot analysis.

column of silica gel eluting with hexanes and AcOEt gradient mixture (10:0 – 0:10) to afford six subfractions (*AT1A* – *AT1F*). *Fr. AT1D* (3.2 g) was purified using preparative HPLC with a gradient of MeOH/H<sub>2</sub>O (20% – 50%, 6 ml/min, 80 min) to afford compounds **1** (*t<sub>R</sub>* 32.7 min; 3.2 mg), **2** (*t<sub>R</sub>* 56.2 min; 728.2 mg), and **3** (*t<sub>R</sub>* 57.8 min; 19.2 mg), respectively.

**(3R,8S)-Heptadec-1-ene-4,6-diyne-3,8-diol (1)**. Colorless oil.  $[\alpha]_D^{20} = +18.7$  (*c* = 0.2, MeOH). NMR: see *Table*. HR-MS: 261.1855 (C<sub>17</sub>H<sub>25</sub>O<sub>2</sub><sup>+</sup>, [*M* – H]<sup>+</sup>; calc. 261.1855).

*Mosher's Esterification*. (*S*)- and (*R*)-MTPA ( $\alpha$ -methoxy- $\alpha$ -(trifluoromethyl)phenylacetyl) esters of **1** were prepared using *Mosher's* esterification method performed in NMR tubes. Compound **1** and 4-(dimethylamino) pyridine (0.2 mg) were transferred into each vial, and this mixture was dried under vacuum. (–)-(*R*) and (+)-(*S*)- $\alpha$ -methoxy- $\alpha$ -(trifluoromethyl)phenylacetyl chloride (MATPCL; 6.0 µl) were immediately added to each vial as solutions in (D<sub>5</sub>) pyridine (0.5 ml) and the vial was sealed and shaken to mix the sample and MTPACL evenly. The vial was permitted to stand at r.t. for 1 h. The soln. of derivatives

was transferred to an NMR tube and monitored by <sup>1</sup>H-NMR [10].

**(S)-MTPA Ester (= (3R,8S)-Heptadec-1-ene-4,6-diyne-3,8-diyl (2S,2'S)-Bis(3,3,3-trifluoro-2-methoxy-2-phenylpropanoate); 1a)**. <sup>1</sup>H-NMR (500 MHz, C<sub>5</sub>D<sub>5</sub>N): 6.6010 (*d*, *J* = 6.3, H–C(3)); 6.0408 – 6.1072 (*m*, H–C(2)); 5.9807 (*t*, *J* = 6.5, H–C(8)); 5.6589 (*d*, *J* = 17.4, H<sub>a</sub>–C(8) – (1)); 5.3712 (*d*, *J* = 10.2, H<sub>b</sub>–C(1)); 1.8419 (*dt*, *J* = 14.5, 7.2, CH<sub>2</sub>(9)); 1.3383 (*d*, *J* = 6.7, CH<sub>2</sub>(10)).

**(R)-MTPA Ester (= (3R,8S)-Heptadec-1-ene-4,6-diyne-3,8-diyl (2R,2'R)-Bis(3,3,3-trifluoro-2-methoxy-2-phenylpropanoate); 1b)**. <sup>1</sup>H-NMR (500 MHz, C<sub>5</sub>D<sub>5</sub>N): 6.6186 (*d*, *J* = 6.3, H–C(3)); 5.9692 – 6.0372 (*m*, H–C(2)); 5.9622 (*t*, *J* = 6.5, H–C(8)); 5.5987 (*d*, *J* = 17.4, H<sub>a</sub>–C(1)); 5.3276 (*d*, *J* = 10.2, H<sub>b</sub>–C(1)); 1.8896 (*dt*, *J* = 14.5, 7.2, CH<sub>2</sub>(9)); 1.4457 (*d*, *J* = 6.7, CH<sub>2</sub>(10)).

#### Cell Culture

RAW264.7 murine macrophage cells were purchased from the Korean Cell Line Bank (*KCLB*, Seoul, Korea). The

cells were cultured in *Dulbecco's* modified *Eagle's* medium supplemented with 100 U/ml of penicillin, 100 U/ml of streptomycin, and 10% fetal bovine serum. The cells were incubated in an atmosphere of 5% CO<sub>2</sub> at 37 °C and were subcultured every 3 days.

### Determination of NO Production

The level of NO production was determined by measuring the amount of nitrite present in cell culture supernatants as described previously [11][12]. Briefly, the RAW264.7 cells (1 × 10<sup>5</sup> cells/well) were treated with or without 1 µg/ml of LPS (*Sigma Chemical Co.*, St. Louis, MO, USA) for 24 h in the presence or absence of the test compounds (0.5 – 25 µM). The cell culture supernate (100 µl) was then reacted with *Griess* reagent (100 µl; 1% sulfanilamide in 5% phosphoric acid and 0.1% naphthylethylenediamine dihydrochloride in dist. H<sub>2</sub>O). The absorbance at 540 nm was measured with a microplate reader (*Emax; Molecular Devices*, Sunnyvale, CA, USA), and the absorption coefficient was calibrated using NaNO<sub>2</sub> solution standard. The IC<sub>50</sub> value was defined as the concentration of sample that reduced absorbance by 50% relative to the vehicle-treated control.

### Immunoblot Analysis

Proteins were extracted from cells in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 1 mM ethylenediamine tetraacetic acid, 1 mM phenylmethyl sulfonyl fluoride, 1 µg/ml leupeptin, 1 mM sodium vanadate, and 150 mM NaCl). To measure iNOS, protein (50 µg per lane) was separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis, and transferred to a polyvinylidene difluoride membrane (*Millipore*, Bedford, MA, USA). The membrane was blocked with 5% skim milk, and then incubated with the corresponding antibody. The antibody for iNOS was obtained from *Santa Cruz Biotechnology* (Santa Cruz, CA, USA). The antibody for  $\alpha$ -tubulin was obtained from *Sigma*. Antibody

for I $\kappa$ B- $\alpha$  was obtained from *Cell Signaling Technology* (Danvers, MA, USA). After binding of an appropriate secondary antibody coupled to horseradish peroxidase, proteins were visualized by enhanced chemiluminescence according to the manufacturer's instructions (*Amersham Pharmacia Biotech*, Little Chalfont, U.K.) [12][13].

### Statistical Analysis

Values are expressed as mean  $\pm$  S.E.M.

### REFERENCES

- [1] C.-M. Kim, M.-K. Sin, D.-K. Ahn, K.-S. Lee, 'Dictionary of Chinese Materia Medica' (in Korean), Jungdam Publishing, Seoul, 1997, p. 255.
- [2] N. Bae, T. Ahn, S. Chung, M. S. Oh, H. Ko, H. Oh, G. Park, H. O. Yang, *J. Ethnopharmacol.* **2011**, *134*, 313.
- [3] M.-H. Ka, E.-H. Choi, H.-S. Chun, K.-G. Lee, *J. Agric. Food Chem.* **2005**, *18*, 4124.
- [4] M. N. Islam, J.-W. Nam, J. Lee, E.-K. Seo, S. B. Han, D.-H. Kim, C. Jin, H. H. Yoo, *Chromatographia* **2009**, *70*, 1079.
- [5] J. W. Chung, R. J. Choi, E.-K. Seo, J.-W. Nam, M.-S. Dong, E. M. Shin, L. Y. Guo, Y. S. Kim, *Arch. Pharmacol. Res.* **2012**, *35*, 723.
- [6] J. R. Zgoda, A. J. Freyer, L. B. Killmer, J. R. Porter, *J. Nat. Prod.* **2001**, *64*, 1348.
- [7] F. Pellati, S. Calò, S. Benvenuti, B. Adinolfi, P. Nieri, M. Melegari, *Phytochemistry* **2006**, *67*, 1359.
- [8] M. C. Yang, H. C. Kwon, Y.-J. Kim, K. R. Lee, H. O. Yang, *J. Nat. Prod.* **2010**, *73*, 801.
- [9] S.-H. Lee, H. Choi, H. Kim, H. Lee, Y.-H. Sung, S.-E. Kim, H.-K. Chang, M.-C. Shin, M.-S. Shin, C.-J. Kim, *Neurol. Res.* **2010**, *32*, 58.
- [10] B.-N. Su, E.-J. Park, Z. H. Mbwambo, B. D. Santarsiero, A. D. Meseccar, H. H. S. Fong, J. M. Pezzuto, A. D. Kinghorn, *J. Nat. Prod.* **2002**, *65*, 1278.
- [11] K. S. Ahn, E. J. Noh, H. L. Zhao, S. H. Jung, S. S. Kang, Y. S. Kim, *Life Sci.* **2005**, *76*, 2315.
- [12] J.-H. Lee, T.-H. Koo, H. Yoon, H. S. Jung, H. Z. Jin, K. Lee, Y.-S. Hong, J. J. Lee, *Biochem. Pharmacol.* **2006**, *72*, 1311.
- [13] J. Lee, N. Tae, J. J. Lee, T. Kim, J.-H. Lee, *Eur. J. Pharmacol.* **2010**, *636*, 173.

Received November 11, 2015

Accepted April 6, 2016